Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry
| Autor: | Thomas Adelsten, Ulrik Tarp, Merete Lund Hetland, Mette Holland-Fischer, Regitse Christensen, Pil Højgaard, Christine Nilsson, Bente Glintborg, Emina Omerovic, Torben Højland Hansen, Lene Dreyer, René Østgård, Jørgen Arendt Jensen, Martin H Petersen, Bjarne Andersen, Anne Gitte Loft, Philip Rask Lage-Hansen |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Immunology Receptors Tumor Necrosis Factor General Biochemistry Genetics and Molecular Biology Etanercept Psoriatic arthritis Rheumatology Internal medicine Epidemiology Adalimumab Humans Immunology and Allergy Medicine Mass index Registries Retrospective Studies business.industry Proportional hazards model Arthritis Psoriatic Smoking Middle Aged medicine.disease Infliximab Surgery Treatment Outcome Antirheumatic Agents Female business Follow-Up Studies medicine.drug Cohort study |
| Zdroj: | Højgaard, P, Glintborg, B, Hetland, M L, Hansen, T H, Lage-Hansen, P R, Petersen, M H, Holland-Fischer, M, Nilsson, C, Loft, A G, Andersen, B N, Adelsten, T, Jensen, J, Omerovic, E, Christensen, R, Tarp, U, Ostgård, R & Dreyer, L 2015, ' Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis : Results from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 74, no. 12, pp. 2130-2136 . https://doi.org/10.1136/annrheumdis-2014-205389 Højgaard, P, Glintborg, B, Hetland, M L, Hansen, T H, Lage-Hansen, P R, Petersen, M H, Holland-Fischer, M, Nilsson, C, Loft, A G R, Andersen, B N, Adelsten, T, Jensen, J, Omerovic, E, Christensen, R, Tarp, U, Ostgård, R & Dreyer, L 2014, ' Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis : results from the DANBIO registry ', Annals of the Rheumatic Diseases . https://doi.org/10.1136/annrheumdis-2014-205389 Højgaard, P, Glintborg, B, Hetland, M L, Hansen, T H, Rask Lage-Hansen, P, Petersen, M H, Holland-Fischer, M, Nilsson, C, Loft, A G, Andersen, B N, Adelsten, T, Jensen, J, Omerovic, E, Christensen, R, Tarp, U, Østgård, R & Dreyer, L 2015, ' Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis : results from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 74, no. 12, pp. 2130-2136 . https://doi.org/10.1136/annrheumdis-2014-205389 |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2014-205389 |
| Popis: | ObjectivesTo investigate the association between tobacco smoking and disease activity, treatment adherence and treatment responses among patients with psoriatic arthritis (PsA) initiating the first tumour necrosis factor α inhibitor therapy (TNFi) in routine care.MethodsObservational cohort study based on the Danish nationwide DANBIO registry. Kaplan–Meier plots, logistic and Cox regression analyses by smoking status (current/previous/never smoker) were calculated for treatment adherence, ACR20/50/70-responses and EULAR-good-response. Additional stratified analyses were performed according to gender and TNFi-subtype (adalimumab/etanercept/infliximab).ResultsAmong 1388 PsA patients included in the study, 1148 (83%) had known smoking status (33% current, 41% never and 26% previous smokers). Median follow-up time was 1.22 years (IQR 0.44–2.96). At baseline, current smokers had lower Body Mass Index (27 kg/m2 (23–30)/28 kg/m2 (24–31)) (median (IQR)), shorter disease duration (3 years (1–8)/5 years (2–10)), lower swollen joint count (2 (0–5)/3 (1–6)), higher visual-analogue-scale (VAS) patient global (72 mm (54–87)/68 mm (50–80)), VAS fatigue (72 mm (51–86)/63 mm (40–77)) and Health Assessment Questionnaire (HAQ) score (1.1 (0.7 to 1.5)/1.0 (0.5 to 1.5)) than never smokers (all pConclusionIn PsA, smokers had worse baseline patient-reported outcomes, shorter treatment adherence and poorer response to TNFi's compared to non-smokers. This was most pronounced in men and in patients treated with infliximab or etanercept. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|